Noxopharm (ASX:NOX) ROCE % : -62.47% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Noxopharm's annualized ROCE % for the quarter that ended in Dec. 2023 was -62.47%.

Noxopharm ROCE % Historical Data

The historical data trend for Noxopharm's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm ROCE % Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-199.10

41.36

-26.31

-56.88

-89.70

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial										-46.01	-68.84	-50.12	-136.59	-62.47

Noxopharm ROCE % Calculation

Noxopharm's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-15.015	/	( ( (26.594 - 2.281)	+	(10.128 - 0.962) )	/ 2 )
	=	-15.015	/	( (24.313	+	9.166)	/ 2 )
	=	-15.015	/	16.7395
	=	-89.70 %

Noxopharm's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-4.942	/	( ( (10.128 - 0.962)	+	(7.156 - 0.5) )	/ 2 )
	=	-4.942	/	( ( 9.166	+	6.656 )	/ 2 )
	=	-4.942	/	7.911
	=	-62.47 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Noxopharm (ASX:NOX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Noxopharm ROCE % Related Terms

Thank you for viewing the detailed overview of Noxopharm's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (ASX:NOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NOXOF:USA

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines